Certainly the impact of this will add value IMHO Rutherrin® has been designed for intravenous administration and has demonstrated preclinically to be highly effective in a number of established animal models of human cancer, including Non-Muscle Invasive Bladder Cancer (“NMIBC”), Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”).
To date, Theralase® has been issued 13 patents for cancer and therapeutic applications and has an additional 34 patents pending in various application stages in the United States, the European Union, Brazil, Russia, India and China.
These countries account for approximately 65% of the world’s Gross Domestic Product (“GDP”) (2015 statistics). If and when these patents are granted, it will allow Theralase® to fully commercialize and protect the Rutherrin® technology in these major healthcare markets.
Sounds Like a Job for Pandora ! Perhaps he would be kind enough to due some digging on stutus of patents.
Research Publications | Theralase Technologies Inc. – Theralase Technologies